Answers are grounded in this paper and cite their sources.
Retrospective study shows that elexacaftor, tezacaftor, and ivacaftor improve exercise performance in patients with cystic fibrosis, suggesting better management options.
" Impact of Elexacaftor/Tezacaftor/Ivacaftor on Cardiopulmonary Exercise Testing in Adults with Cystic Fibrosis—A Retrospective Study." Annals of the American Thoracic Society, 0(ja), pp.
No takes yet. Share an insight, caveat, or question.
Auth et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: